Dalcinonacog alfa

DB17707InvestigationalProtein Based Therapies

Dalcinonacog alfa is a recombinant human factor IX (FIX) variant. It is being investigated for the treatment of hemophilia B.

Mechanism: Pharmacologically active on Coagulation factor IX
Curator reviewed
Code names: CB-2679d · CB-FIX · ISU-304

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dalcinonacog alfa, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.